Primary Sclerosing Cholangitis — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
MLPH/RAB3A accelerates the differentiation of pancreatic stem cells to islet β-cells to control blood glucose in diabetic rats.
Shan Junling et al. — Organogenesis (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41774510/
- 2.
Recurrent ileocolic variceal hemorrhage treated with superselective Onyx embolization: A case report.
Babaei Mohammad Reza et al. — Radiology case reports (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41798667/
- 3.
Subclinical psoriatic arthritis: concepts, dilemmas, and research needs.
Kharouf Fadi et al. — Annals of the rheumatic diseases (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41934034/
- 4.
Generative AI-Driven Accelerated Discovery of Passivation Molecules for Perovskite Solar Cells.
Fajar Adroit T N et al. — Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41926641/
- 5.
Partial occupation of selenium in porous carbon enhances selenium utilization for potassium-ion batteries.
Liu Lingli et al. — Chemical communications (Cambridge, England) (2 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41924981/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Recruiting — Phase 2 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06833073
- 2.
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Recruiting — Phase 3 — AbbVie
https://clinicaltrials.gov/study/NCT05843643
- 3.
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
Recruiting — Phase 2 — CSL Behring
https://clinicaltrials.gov/study/NCT05485961
- 4.
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Recruiting — Phase 3 — AbbVie
https://clinicaltrials.gov/study/NCT05889182
- 5.
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Recruiting — Phase 3 — Pfizer
https://clinicaltrials.gov/study/NCT07028853
- 6.
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Recruiting — Phase 3 — AbbVie
https://clinicaltrials.gov/study/NCT06012240
- 7.
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT06806592
- 8.
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Recruiting — Phase 3 — Bayer
https://clinicaltrials.gov/study/NCT04464226
- 9.
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Recruiting — Phase 3 — Boehringer Ingelheim
https://clinicaltrials.gov/study/NCT07064473
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis is a chronic progressive disease of the bile ducts characterised by inflammation and fibrosis, leading to strictures, liver failure, and a significantly elevated risk of cholangiocarcinoma. It is strongly associated with inflammatory bowel disease, particularly ulcerative colitis. No effective medical treatment exists; liver transplantation is the only definitive therapy for advanced disease.
Most Recent Research
BACKGROUND: This study aimed to determine the potential mechanism by which pancreatic stem cell-derived beta cells (PSCs-β) assist in the body's glucose-lowering capacity in type 1 diabetes (T1D) rats. METHODS: We screened the transcriptomic changes in the pancreatic islets of T1D mice to extract key genes from the GSE169275 dataset. Cell proliferation, cell cycle distribution, apoptosis, PSC-β differentiation ability, and insulin production levels were analyzed after MLPH overexpression/knockdown in PSCs. PSC-β-overexpressing MLPH were transplanted into T1D rats, and the changes in fasting blood glucose level, glucose tolerance and insulin, glucagon and C-peptide contents were examined. After the target genes of MLPH were analysed using the database, immunoprecipitation was introduced for validation. Whether RAB3A is involved in the regulatory effects of MLPH on the proliferation and differentiation of PSCs was further verified. RESULTS: MLPH overexpression further enhanced the proliferation of PSCs, inhibited apoptosis and accelerated the differentiation of PSCs to PSC-β cells and insulin secretion. After the transplantation of MLPH-overexpressing PSC-β cells, the pancreatic islet tissue damage was restored, the insulin expression was substantially elevated and the glucagon content decreased. RAB3A knockdown counteracted the effects of MLPH on the proliferation, differentiation and insulin secretion of PSCs. CONCLUSION: MLPH overexpression is favourable for the differentiation of PSCs to insulin β-cells. Transplantation of MLPH-overexpressing PSC-β cells restored the ability of T1D rats to manage a glycemic load by promoting RAB3A expression.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.